{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:46:52Z","timestamp":1788173212341,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.euf.2022.02.006","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T18:26:41Z","timestamp":1647282401000},"page":"1643-1649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non\u2013muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker"],"prefix":"10.1016","volume":"8","author":[{"given":"Morgan","family":"Roupr\u00eat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart R.C.","family":"McCracken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Dudderidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Stockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashleigh","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Sieverink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicien","family":"Vani\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Allasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Montanari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2022.02.006_b0005","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00345-018-2550-x","article-title":"Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories","volume":"37","author":"Mossanen","year":"2019","journal-title":"World J Urol"},{"issue":"165","key":"10.1016\/j.euf.2022.02.006_b0010","first-page":"e19","article-title":"Long-term oncological outcomes of an active surveillance program in recurrent low grade Ta bladder cancer","volume":"34","author":"Hern\u00e1ndez","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2022.02.006_b0015","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.urology.2019.04.036","article-title":"Overuse of cystoscopic surveillance among patients with low-risk non\u2013muscle-invasive bladder cancer \u2013 a national study of patient, provider, and facility factors","volume":"131","author":"Han","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.euf.2022.02.006_b0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230417","article-title":"The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC)","volume":"15","author":"Rezaee","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.euf.2022.02.006_b0025","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1002\/cncr.32185","article-title":"The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, non\u2013muscle-invasive bladder cancer","volume":"125","author":"Schroeck","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2022.02.006_b0030","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.urolonc.2020.11.014","article-title":"Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: a review","volume":"39","author":"Wolfs","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2022.02.006_b0035","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/JU.0000000000001084","article-title":"Diagnostic accuracy of MCM5 for the detection of recurrence in nonmuscle invasive bladder cancer followup: a blinded, prospective cohort, multicenter European study","volume":"204","author":"Roupret","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2022.02.006_b0040","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/bju.15194","article-title":"Comparison of the performance of ADXBLADDER test and urinary cytology in the follow up of non-muscle invasive bladder cancer: a blinded prospective multicentric study","volume":"127","author":"Gontero","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2022.02.006_b0045","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1530\/EJE-20-1239","article-title":"Introduction to diagnostic test accuracy studies","volume":"184","author":"Sitch","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.euf.2022.02.006_b0050","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","article-title":"Receiver operating characteristic curve in diagnostic test assessment","volume":"5","author":"Mandrekar","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.euf.2022.02.006_b0055","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.euf.2022.02.006_b0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.02.006_b0065","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00345-018-2380-x","article-title":"An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer","volume":"36","author":"Soria","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2022.02.006_b0070","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.euo.2018.06.011","article-title":"Performance of the Bladder EpiCheck\u2122 methylation test for patients under surveillance for non\u2013muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial","volume":"1","author":"Witjes","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2022.02.006_b0075","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cncy.22246","article-title":"Comparison of 2 new real-time polymerase chain reaction\u2013based urinary markers in the follow-up of patients with non\u2013muscle-invasive bladder cancer","volume":"128","author":"Trenti","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.euf.2022.02.006_b0080","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.eururo.2018.11.055","article-title":"Prospective validation of an mRNA-based urine test for surveillance of patients with bladder cancer","volume":"75","author":"van Valenberg","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.02.006_b0085","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/jclinpath-2018-205393","article-title":"Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer","volume":"72","author":"Delia","year":"2019","journal-title":"J Clin Pathol"},{"issue":"77","key":"10.1016\/j.euf.2022.02.006_b0090","first-page":"e9","article-title":"Prospective validation of clinical usefulness of a novel mRNA-based urine test (Xpert\u00ae Bladder Cancer Monitor) for surveillance in non muscle invasive bladder cancer","volume":"39","author":"Elsawy","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2022.02.006_b0095","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/bju.15418","article-title":"Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert\u00ae Bladder Cancer Monitor) for surveillance in patients with non-muscle-invasive bladder cancer","volume":"128","author":"Cowan","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2022.02.006_b0100","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/bju.14673","article-title":"Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer","volume":"123","author":"D\u2019Andrea","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2022.02.006_b0105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.juro.2017.08.091","article-title":"Active surveillance for low risk nonmuscle invasive bladder cancer: a confirmatory and resource consumption study from the BIAS project","volume":"199","author":"Hurle","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2022.02.006_b0110","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.urology.2008.12.061","article-title":"Safety of active surveillance program for recurrent nonmuscle-invasive bladder carcinoma","volume":"73","author":"Hern\u00e1ndez","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.euf.2022.02.006_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14040","article-title":"Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer","volume":"14","author":"Mowatt","year":"2010","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.euf.2022.02.006_b0120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3233\/BLC-201535","article-title":"A randomized feasibility trial comparing surveillance regimens for patients with low and low-intermediate risk non-muscle invasive bladder cancer","volume":"7","author":"Reyes","year":"2021","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euf.2022.02.006_b0125","doi-asserted-by":"crossref","first-page":"E210","DOI":"10.5489\/cuaj.4922","article-title":"Replacing surveillance cystoscopy with urinary biomarkers in follow up of patients with non-muscle-invasive bladder cancer: patients\u2019 and urologic oncologists\u2019 perspectives","volume":"12","author":"Sayyid","year":"2018","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euf.2022.02.006_b0130","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.urolonc.2020.01.006","article-title":"Toward noninvasive follow-up of low-risk bladder cancer \u2013 rationale and concept of the UroFollow trial","volume":"38","author":"Enderska-S\u00f6der","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2022.02.006_b0135","series-title":"Poster P0724 presented at the 36th Annual European Association of Urology Congress","article-title":"Anticipatory effects of ADXBLADDER test results in the follow up of cystoscopy negative non muscle invasive bladder cancer patients in a large multicentric European cohort","author":"Roupr\u00eat","year":"2021"},{"key":"10.1016\/j.euf.2022.02.006_b0140","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1007\/s00345-020-03569-2","article-title":"Follow-up in non-muscle invasive bladder cancer: facts and future","volume":"39","author":"Witjes","year":"2021","journal-title":"World J Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456922000517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456922000517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:52:02Z","timestamp":1762498322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456922000517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2405456922000517"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2022.02.006","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non\u2013muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2022.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}